{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Brolucizumab 6 mg",
        "type": {
          "id": "1e976306-27fd-4cd5-a76e-ad366f27c79b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "9e04bda3-d81b-4a49-b96e-546be71c4623",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Anti-VEGF single-chain antibody fragment (scFv) for proliferative diabetic retinopathy",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Panretinal photocoagulation (PRP)",
        "type": {
          "id": "64ff38cf-a24a-4745-9fe3-a35fdd4f3fd4",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "84d15c1b-1c91-4060-90d5-9cf9655914a4",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Standard of care laser treatment for proliferative diabetic retinopathy",
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Topical ocular medications",
        "type": {
          "id": "9e2e6bfb-a5bf-41e4-9b9d-5fd7023a0661",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a0d7a78b-eb57-4770-b7d1-184548a06855",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted during the study, including corticosteroids",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Corticosteroids (non-ocular)",
        "type": {
          "id": "8f1effb7-e871-4aaa-980a-648f303416b9",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "7a39bd52-e5e5-426a-a4cd-455da95943b6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted via intra-nasal, inhaled, intra-articular, or non-extensive dermal routes",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Anti-VEGF therapy (other than study drug)",
        "type": {
          "id": "23a3b0ef-07f2-4084-a52f-47b1c2f3240e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "d2f38bb1-1ece-474a-9d96-6168eae09ee7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited in the study eye and systemically",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Fluocinolone acetonide intravitreal implant",
        "type": {
          "id": "6c4646b3-8142-4a60-b698-e56faed57488",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "56059df2-aafc-4151-a2f5-f9b1af3c4576",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited prior to baseline and during study"
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Brolucizumab",
        "administrableDoseForm": {
          "id": "2fa890e7-fb9a-4f81-a4d5-7553e6ef48b1",
          "code": "C42986",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Solution",
          "standardCode": {
            "id": "661f686b-ff18-46cf-bd5a-2d3c9371a0ba",
            "code": "C42986",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Solution",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "64653879-4fab-47d0-88f9-104a2444ff8d",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "6 mg/0.05 mL",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Novartis"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Brolucizumab Loading Phase",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "Every 6 weeks (3 doses)",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Baseline, Week 6, and Week 12"
      },
      {
        "id": "admin_2",
        "name": "Brolucizumab Maintenance Phase",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "Every 12 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Week 18 through Week 90"
      },
      {
        "id": "admin_3",
        "name": "Brolucizumab Extension Phase",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "Extended by 6-week increments up to every 24 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "From Week 48 onwards based on disease stability"
      },
      {
        "id": "admin_4",
        "name": "PRP Initial Treatment",
        "instanceType": "Administration",
        "dose": "1500-5000 burns",
        "doseFrequency": "1 to 4 sessions",
        "route": {
          "code": "Topical",
          "codeSystem": "USDM",
          "decode": "Topical"
        },
        "duration": "Up to Week 12"
      },
      {
        "id": "admin_5",
        "name": "PRP Maintenance (PRN)",
        "instanceType": "Administration",
        "dose": "As needed",
        "doseFrequency": "As needed (Pro re nata)",
        "route": {
          "code": "Topical",
          "codeSystem": "USDM",
          "decode": "Topical"
        },
        "duration": "From Week 18 to Week 90"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Brolucizumab",
        "instanceType": "Substance",
        "description": "Single-chain antibody fragment (scFv) inhibitor of vascular endothelial growth factor A (VEGF-A)"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Conventional lasers or automated pattern delivery systems",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 6,
      "productCount": 1,
      "deviceCount": 1
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Brolucizumab 6 mg",
        "role": "Investigational Product",
        "description": "Anti-VEGF single-chain antibody fragment (scFv) for proliferative diabetic retinopathy"
      },
      {
        "name": "Panretinal photocoagulation (PRP)",
        "role": "Comparator",
        "description": "Standard of care laser treatment for proliferative diabetic retinopathy"
      },
      {
        "name": "Topical ocular medications",
        "role": "Concomitant Medication",
        "description": "Permitted during the study, including corticosteroids"
      },
      {
        "name": "Corticosteroids (non-ocular)",
        "role": "Concomitant Medication",
        "description": "Permitted via intra-nasal, inhaled, intra-articular, or non-extensive dermal routes"
      },
      {
        "name": "Anti-VEGF therapy (other than study drug)",
        "role": "Concomitant Medication",
        "description": "Prohibited in the study eye and systemically"
      },
      {
        "name": "Fluocinolone acetonide intravitreal implant",
        "role": "Concomitant Medication",
        "description": "Prohibited prior to baseline and during study"
      }
    ],
    "products": [
      {
        "name": "Brolucizumab",
        "doseForm": "Solution for injection",
        "strength": "6 mg/0.05 mL",
        "manufacturer": "Novartis"
      }
    ],
    "substances": [
      {
        "name": "Brolucizumab",
        "description": "Single-chain antibody fragment (scFv) inhibitor of vascular endothelial growth factor A (VEGF-A)"
      }
    ],
    "administrations": [
      {
        "name": "Brolucizumab Loading Phase",
        "dose": "6 mg",
        "frequency": "Every 6 weeks (3 doses)",
        "route": "Intravitreal",
        "duration": "Baseline, Week 6, and Week 12"
      },
      {
        "name": "Brolucizumab Maintenance Phase",
        "dose": "6 mg",
        "frequency": "Every 12 weeks",
        "route": "Intravitreal",
        "duration": "Week 18 through Week 90"
      },
      {
        "name": "Brolucizumab Extension Phase",
        "dose": "6 mg",
        "frequency": "Extended by 6-week increments up to every 24 weeks",
        "route": "Intravitreal",
        "duration": "From Week 48 onwards based on disease stability"
      },
      {
        "name": "PRP Initial Treatment",
        "dose": "1500-5000 burns",
        "frequency": "1 to 4 sessions",
        "route": "Topical (Laser)",
        "duration": "Up to Week 12"
      },
      {
        "name": "PRP Maintenance (PRN)",
        "dose": "As needed",
        "frequency": "As needed (Pro re nata)",
        "route": "Topical (Laser)",
        "duration": "From Week 18 to Week 90"
      }
    ],
    "devices": [
      {
        "name": "Conventional lasers or automated pattern delivery systems",
        "manufacturer": "Not specified",
        "purpose": "Administration of panretinal photocoagulation"
      }
    ]
  }
}